Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $8.17

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.1667.

JSPR has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Piper Sandler began coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 price target for the company. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $0.70 on Monday. The firm has a 50-day simple moving average of $0.65 and a 200-day simple moving average of $0.85. The stock has a market capitalization of $23.28 million, a price-to-earnings ratio of -0.44 and a beta of 3.02. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $2.87.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, equities research analysts expect that Jasper Therapeutics will post -1.32 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics during the first quarter worth about $46,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics in the 2nd quarter valued at about $78,000. Panagora Asset Management Inc. purchased a new stake in shares of Jasper Therapeutics in the 4th quarter valued at approximately $35,000. Voleon Capital Management LP purchased a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at approximately $50,000. Finally, XTX Topco Ltd acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $152,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.